IMV
ShareCopied to clipboardIMV is a company. It is a public company in Dartmouth, Canada. It was founded in 2000 and its current CEO is Andrew Hall. It is part of the Health Care sector, specifically in the Biotechnology industry.
Key facts
- city: Dartmouth
- state: NS
- country: Canada
- employees: 97 people
- revenues: -53000 $
- company type: public
- sector: Health Care
- industry: Biotechnology
- foundation year: 2000
- CEO: Andrew Hall
- ESG score: 67.98 / 100
See more facts
Extract data
Download datasets about IMV:
Dataset of stocks from IMV:
IMV is one of the companies in Canada, companies in Biotechnology, companies in Health Care, companies in Dartmouth and 3,456,808 companies in our database.
Talking Points
- IMV Inc.
- Clinical stage biotech developing a portfolio of immune-educating therapies based on our DPX® platform to treat solid and hematological cancers
- IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.